sorafenib tosilate: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
sorafenib tosilate: clinical details
Prescribing considerations
- Treatment requires supervision by a clinician experienced in anticancer therapy.
- Assess cardiovascular disease, hypertension, bleeding risk, diabetes, wound-healing concerns, aneurysm or dissection risk, QT-risk factors and hepatic impairment.
- Plan specialist interruption around major surgery and resume only after adequate wound healing.
- For differentiated thyroid carcinoma, reassess benefit and tolerability regularly and consider tumour infiltration affecting the airway or oesophagus.
Contraindications and cautions
- Hypersensitivity to sorafenib or any product excipient.
Monitoring
- Blood pressure, especially early in treatment.
- Skin and hand–foot toxicity, gastrointestinal toxicity, bleeding and infection.
- Renal function, hydration and electrolytes where clinically indicated.
- Liver tests, blood count, glucose in patients with diabetes and ECG/electrolytes in those at risk of QT prolongation.
- Calcium and thyroid-stimulating hormone in differentiated thyroid carcinoma.
- Clinical and radiological response and overall tolerability.
Clinical pharmacology
Sorafenib inhibits tumour-cell and angiogenic kinases, including RAF, VEGFR and PDGFR pathways. It is highly protein-bound, metabolised mainly through hepatic CYP3A4 oxidation and UGT1A9 glucuronidation, and undergoes enterohepatic recycling and predominantly faecal elimination.
Formulation and product differences
- The selected product is a red, film-coated oral tablet containing sorafenib as the tosylate salt.
- Appearance, excipients, packaging and storage requirements may differ between sorafenib products; check the product-specific SmPC.
sorafenib tosilate preparations and strengths
Tablet
Route: Oral
Strengths: 200 mg
sorafenib tosilate interactions
The cancer team should review prescribed, non-prescribed and herbal products before treatment.
Rifampicin, phenytoin, carbamazepine, phenobarbital, dexamethasone or St John’s wort
These enzyme inducers may lower sorafenib exposure and reduce its effect.
Warfarin or phenprocoumon
Bleeding or INR changes may occur, so anticoagulation and clinical bleeding require close monitoring.
Neomycin and some other antibiotics affecting gut bacteria
They may reduce sorafenib absorption or exposure.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.